NeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Tuesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NURO opened at $3.70 on Tuesday. The business has a 50 day simple moving average of $3.77 and a 200-day simple moving average of $3.74. The stock has a market capitalization of $7.44 million, a P/E ratio of -0.59 and a beta of 2.30. NeuroMetrix has a 12 month low of $2.70 and a 12 month high of $7.88.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($1.67) EPS for the quarter. NeuroMetrix had a negative net margin of 151.51% and a negative return on equity of 39.85%. The business had revenue of $1.09 million during the quarter.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC acquired a new stake in NeuroMetrix, Inc. (NASDAQ:NURO) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned approximately 2.80% of NeuroMetrix at the end of the most recent reporting period. Institutional investors own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.